JP2016526050A5 - - Google Patents

Download PDF

Info

Publication number
JP2016526050A5
JP2016526050A5 JP2016518053A JP2016518053A JP2016526050A5 JP 2016526050 A5 JP2016526050 A5 JP 2016526050A5 JP 2016518053 A JP2016518053 A JP 2016518053A JP 2016518053 A JP2016518053 A JP 2016518053A JP 2016526050 A5 JP2016526050 A5 JP 2016526050A5
Authority
JP
Japan
Prior art keywords
level
lyso
spm
therapeutic agent
biological sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016518053A
Other languages
English (en)
Japanese (ja)
Other versions
JP6457501B2 (ja
JP2016526050A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/041405 external-priority patent/WO2014197859A1/en
Publication of JP2016526050A publication Critical patent/JP2016526050A/ja
Publication of JP2016526050A5 publication Critical patent/JP2016526050A5/ja
Application granted granted Critical
Publication of JP6457501B2 publication Critical patent/JP6457501B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016518053A 2013-06-07 2014-06-06 酸性スフィンゴミエリナーゼ障害のマーカーおよびその使用 Active JP6457501B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361832302P 2013-06-07 2013-06-07
US61/832,302 2013-06-07
PCT/US2014/041405 WO2014197859A1 (en) 2013-06-07 2014-06-06 Marker for acid sphingomyelinase disorders and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018236856A Division JP6835806B2 (ja) 2013-06-07 2018-12-19 酸性スフィンゴミエリナーゼ障害のマーカーおよびその使用

Publications (3)

Publication Number Publication Date
JP2016526050A JP2016526050A (ja) 2016-09-01
JP2016526050A5 true JP2016526050A5 (https=) 2017-07-13
JP6457501B2 JP6457501B2 (ja) 2019-01-23

Family

ID=51062988

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016518053A Active JP6457501B2 (ja) 2013-06-07 2014-06-06 酸性スフィンゴミエリナーゼ障害のマーカーおよびその使用
JP2018236856A Active JP6835806B2 (ja) 2013-06-07 2018-12-19 酸性スフィンゴミエリナーゼ障害のマーカーおよびその使用
JP2021015390A Active JP7414750B2 (ja) 2013-06-07 2021-02-03 酸性スフィンゴミエリナーゼ障害のマーカーおよびその使用
JP2023220385A Active JP7830414B2 (ja) 2013-06-07 2023-12-27 酸性スフィンゴミエリナーゼ障害のマーカーおよびその使用
JP2025244095A Pending JP2026041958A (ja) 2013-06-07 2025-12-10 酸性スフィンゴミエリナーゼ障害のマーカーおよびその使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018236856A Active JP6835806B2 (ja) 2013-06-07 2018-12-19 酸性スフィンゴミエリナーゼ障害のマーカーおよびその使用
JP2021015390A Active JP7414750B2 (ja) 2013-06-07 2021-02-03 酸性スフィンゴミエリナーゼ障害のマーカーおよびその使用
JP2023220385A Active JP7830414B2 (ja) 2013-06-07 2023-12-27 酸性スフィンゴミエリナーゼ障害のマーカーおよびその使用
JP2025244095A Pending JP2026041958A (ja) 2013-06-07 2025-12-10 酸性スフィンゴミエリナーゼ障害のマーカーおよびその使用

Country Status (29)

Country Link
US (4) US10022428B2 (https=)
EP (2) EP3584580A1 (https=)
JP (5) JP6457501B2 (https=)
KR (3) KR102292298B1 (https=)
CN (2) CN105474017A (https=)
AU (5) AU2014274670B2 (https=)
CA (1) CA2914751C (https=)
CL (1) CL2015003563A1 (https=)
CR (1) CR20150638A (https=)
DK (1) DK3004896T3 (https=)
EA (1) EA035342B1 (https=)
ES (1) ES2762608T3 (https=)
HR (1) HRP20192246T1 (https=)
HU (1) HUE047863T2 (https=)
IL (3) IL298675B2 (https=)
LT (1) LT3004896T (https=)
MA (1) MA38638B1 (https=)
MX (1) MX370570B (https=)
MY (1) MY185990A (https=)
NZ (1) NZ754328A (https=)
PH (1) PH12015502687A1 (https=)
PL (1) PL3004896T3 (https=)
PT (1) PT3004896T (https=)
RS (1) RS59677B1 (https=)
SG (2) SG11201509622WA (https=)
SI (1) SI3004896T1 (https=)
UA (1) UA120591C2 (https=)
WO (1) WO2014197859A1 (https=)
ZA (1) ZA201508630B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3998078T1 (sl) * 2009-08-28 2026-02-27 Genzyme Corporation Encimsko nadomestno zdravljenje z naraščajočim odmerkom za zdravljenje pomanjkanja kisle sfingomielinaze
ES2762608T3 (es) * 2013-06-07 2020-05-25 Genzyme Corp Marcador para trastornos de esfingomielinasa ácida y usos del mismo
JP6984854B2 (ja) * 2015-10-08 2021-12-22 国立大学法人千葉大学 ニーマン・ピック病c型を予防または治療するための医薬組成物
KR20250025051A (ko) 2017-08-24 2025-02-20 사노피 산성 스핑고미엘린분해효소 결핍증 환자에서의 비정상적 골병태의 치료
CR20200129A (es) 2017-10-02 2020-08-22 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas
HUE071194T2 (hu) * 2019-05-31 2025-08-28 Genzyme Corp Kétdimenziós LC-MS/MS rendszerek
WO2024026390A2 (en) * 2022-07-28 2024-02-01 Wylder Nation Foundation Compositions and methods for diagnosing, treating, and preventing lysosomal storage diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082781A (en) 1976-06-04 1978-04-04 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide
US4039388A (en) 1976-06-04 1977-08-02 The United States Of America As Represented By The Government Diagnostic test for Niemann-Pick disease
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
AR034413A1 (es) 2000-08-25 2004-02-25 Nestor Abel Chamoles Metodo para determinar la actividad de las enzimas lisosomales
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7615224B2 (en) 2004-12-02 2009-11-10 Women's And Children's Hospital Multiplex-bead complex for determination of lysosomal storage disorders
JP2006214731A (ja) * 2005-02-01 2006-08-17 Institute Of Physical & Chemical Research スフィンゴミエリンの検出方法
WO2007078806A2 (en) 2005-12-15 2007-07-12 The Research Foundation Of State University Of New York Enzymatic methods for measuring plasma and tissue sphingomylelin and phosphatidylcholine
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
US8026099B2 (en) 2007-07-26 2011-09-27 Washington University Lipid profile as a biomarker for early detection of neurological disorders
US8497122B2 (en) 2008-04-11 2013-07-30 Washington University Biomarkers for Niemann-pick C disease and related disorders
SI3998078T1 (sl) * 2009-08-28 2026-02-27 Genzyme Corporation Encimsko nadomestno zdravljenje z naraščajočim odmerkom za zdravljenje pomanjkanja kisle sfingomielinaze
JP2013002933A (ja) 2011-06-16 2013-01-07 Hitachi Plant Technologies Ltd 3次元測位システム
BR112014009223B1 (pt) * 2011-11-15 2021-04-06 Centogene Gmbh Métodos para o diagnóstico da doença de niemann-pick, método para determinação do curso da doença de niemann-pick, método para determinação da eficácia de pelo menos um tratamento, uso de análise espectrométrica de massa e kit
JP6660291B2 (ja) * 2013-05-14 2020-03-11 セントジーン アーゲー ニーマン・ピック病の診断のための方法
ES2762608T3 (es) 2013-06-07 2020-05-25 Genzyme Corp Marcador para trastornos de esfingomielinasa ácida y usos del mismo

Similar Documents

Publication Publication Date Title
JP2016526050A5 (https=)
Garg et al. Subacute sclerosing panencephalitis
Ortega et al. Role of HIV in amyloid metabolism
Macrez et al. Mechanisms of glutamate toxicity in multiple sclerosis: biomarker and therapeutic opportunities
Vlisides et al. Neurotoxicity of general anesthetics: an update
Silva et al. Muscle dysfunction in the long coronavirus disease 2019 syndrome: Pathogenesis and clinical approach
Dursun et al. The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease
Mathis et al. Management and therapeutic perspectives in amyotrophic lateral sclerosis
McClafferty et al. Approach to critical illness myopathy and polyneuropathy in the older SARS-CoV-2 patients
Smith et al. Effects of a novel sodium channel blocker, GSK2339345, in patients with refractory chronic cough
Wood et al. Mannitol challenge for assessment of airway responsiveness, airway inflammation and inflammatory phenotype in asthma
JP2026041958A5 (https=)
JP2016516074A5 (https=)
CN108289930A (zh) 用于治疗神经退行性和神经炎性病症的方法和组合物
Gromova et al. Direct and indirect neurological signs of COVID-19
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
Patil et al. Nintedanib as an antifibrotic in post COVID lung fibrosis: Are we really overestimating
Gao et al. Effectiveness and tolerability of adjunctive perampanel in the treatment of pediatric patients with uncontrolled epilepsy: a retrospective, single-center, real-world study
JP2017519008A5 (https=)
KR101619238B1 (ko) 체내 단백질 응집체의 용해를 이용한 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환 또는 질병을 진단하는 혈액진단키트
Shah et al. Chronic kidney disease–associated pruritus: what is known and its application in children
Levin et al. Efficacy of akatinol memantine in moderate cognitive impairments
WO2024011094A1 (en) Regimen for treating amyotrophic lateral sclerosis having onset 24 months prior to treatment
Taniguchi et al. Chest pain relieved with a bronchodilator or other asthma drugs
US20250099544A1 (en) Treatment of Type 1 Diabetes and Other Conditions Using the Gut Microbiome